Golimumab 100 mg/ML
RxNorm 848158
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 848158 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: golimumab 100 mg/ML.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDCPrescribable
Semantic Clinical Drug Component (SCDC):
Golimumab 100 mg/ML
(Atom ID: 2967320)
Patient Education
Golimumab Injection
Golimumab injection (Simponi) is used to relieve the symptoms of certain autoimmune disorders (conditions in which the immune system attacks healthy parts of the body and causes pain, swelling, and damage) including: rheumatoid arthritis (condition in which the body attacks its own joints causing pain, swelling, and loss of function) along with methotrexate (Otrexup, Rasuvo, Trexall) in adults, ankylosing spondylitis (condition in which the body attacks the joints of the spine and other areas causing pain and joint damage) in adults, psoriatic arthritis (condition that causes joint pain and swelling and scales on the skin) alone or in combination with methotrexate in adults, and ulcerative colitis (a condition which causes swelling and sores in the lining of the colon [large intestine] and rectum) when other medications and treatments did not help or could not be tolerated. Golimumab injection (Simponi Aria) is also used to relieve the symptoms of certain autoimmune disorders including: rheumatoid arthritis (condition in which the body attacks its own joints causing pain, swelling, and loss of function) along with methotrexate (Otrexup, Rasuvo, Trexall) in adults, ankylosing spondylitis (condition in which the body attacks the joints of the spine and other areas causing pain and joint damage) in adults, psoriatic arthritis (condition that causes joint pain and swelling and scales on the skin) in adults and children 2 years of age and older, polyarticular juvenile idiopathic arthritis (PJIA; a type of childhood arthritis that affects five or more joints during the first six months of the condition, causing pain, swelling, and loss of function) in children 2 years of age and older. Golimumab is in a class of medications called tumor necrosis factor (TNF) inhibitors. It works by blocking the action of TNF, a substance in the body that causes inflammation.
[Learn More]
* Please review the disclaimer below.
